Stock Ideas
New
Stocks
Funds
Screener
Sectors
Watchlists
APRE

APRE - Aprea Therapeutics Inc Stock Price, Fair Value and News

4.10USD-0.13 (-3.07%)Market Closed

Market Summary

APRE
USD4.10-0.13
Market Closed
-3.07%

APRE Stock Price

View Fullscreen

APRE RSI Chart

APRE Valuation

Market Cap

23.0M

Price/Earnings (Trailing)

-1.81

Price/Sales (Trailing)

39.38

Price/Free Cashflow

-1.74

APRE Price/Sales (Trailing)

APRE Profitability

Return on Equity

-43.97%

Return on Assets

-38.3%

Free Cashflow Yield

-57.59%

APRE Fundamentals

APRE Revenue

Revenue (TTM)

583.2K

APRE Earnings

Earnings (TTM)

-12.7M

Earnings Growth (Yr)

35.84%

Earnings Growth (Qtr)

18.39%

Breaking Down APRE Revenue

Last 7 days

-7.0%

Last 30 days

-25.8%

Last 90 days

-29.4%

Trailing 12 Months

28.5%

How does APRE drawdown profile look like?

APRE Financial Health

Current Ratio

11.15

APRE Investor Care

Shares Dilution (1Y)

45.52%

Diluted EPS (TTM)

-3.3

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
20240000
2023000583.2K

Tracking the Latest Insider Buys and Sells of Aprea Therapeutics Inc

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
May 01, 2024
mirza nadeem q.
acquired
-
-
6,730
chief medical officer
Mar 28, 2024
gilad oren
acquired
-
-
6,725
president, ceo
Mar 28, 2024
hamill john p.
acquired
-
-
3,365
srvp/cfo/prin fin & acct ofcr
Mar 13, 2024
gilad oren
bought
14,580
7.29
2,000
president, ceo
Mar 13, 2024
seizinger bernd r.
bought
50,009
7.29
6,860
-
Mar 13, 2024
hamill john p.
bought
7,362
7.29
1,010
srvp/cfo/prin fin & acct ofcr
Mar 13, 2024
henneman john b iii
bought
50,009
7.29
6,860
-
Aug 23, 2023
henneman john b iii
acquired
-
-
500
-
Aug 23, 2023
peters richard
acquired
-
-
500
-
Aug 23, 2023
grissinger michael
acquired
-
-
500
-

1–10 of 50

Which funds bought or sold APRE recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
May 15, 2024
Walleye Capital LLC
sold off
-100
-376,000
-
-%
May 15, 2024
MORGAN STANLEY
added
55.76
98,487
179,412
-%
May 15, 2024
Royal Bank of Canada
reduced
-94.16
-190,000
17,000
-%
May 15, 2024
BANK OF AMERICA CORP /DE/
reduced
-51.83
-4,803
10,477
-%
May 15, 2024
DAFNA Capital Management LLC
new
-
917,694
917,694
0.21%
May 15, 2024
Tower Research Capital LLC (TRC)
added
105
4,957
7,533
-%
May 15, 2024
SPHERA FUNDS MANAGEMENT LTD.
new
-
1,806,300
1,806,300
0.25%
May 15, 2024
Nantahala Capital Management, LLC
new
-
1,376,530
1,376,530
0.08%
May 15, 2024
Sio Capital Management, LLC
reduced
-1.21
534,474
1,850,470
0.55%
May 14, 2024
AIGH Capital Management LLC
added
54.39
1,863,110
3,504,820
1.05%

1–10 of 31

Are Funds Buying or Selling APRE?

Are funds buying APRE calls or puts?
Calls
Puts
No. of funds holding Calls - Puts
Net Call Options
No. of funds that own APRE
No. of Funds

Unveiling Aprea Therapeutics Inc's Major ShareHolders

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
Feb 14, 2024
sio capital management, llc
7.49%
280,000
SC 13G
Feb 07, 2024
hirschman orin
9.4%
349,300
SC 13G/A
Mar 03, 2023
hirschman orin
9.2%
345,000
SC 13G
Nov 15, 2022
healthcap vii, l.p.
4.5%
2,366,104
SC 13D/A
Jun 30, 2022
healthcap vii, l.p.
10.1%
2,366,104
SC 13D/A
Feb 14, 2022
redmile group, llc
0%
0
SC 13G/A
Feb 11, 2022
versant ventures v, llc
0.0%
0
SC 13G/A
Oct 15, 2021
healthcap vii, l.p.
11.2%
2,366,104
SC 13D/A
Oct 12, 2021
morgan stanley
0.9%
184,964
SC 13G/A
Mar 24, 2021
morgan stanley
5.1%
1,072,411
SC 13G

Recent SEC filings of Aprea Therapeutics Inc

View All Filings
Date Filed Form Type Document
May 14, 2024
10-Q
Quarterly Report
May 14, 2024
8-K
Current Report
May 02, 2024
3
Insider Trading
May 02, 2024
4
Insider Trading
Apr 30, 2024
424B3
Prospectus Filed
Apr 29, 2024
EFFECT
EFFECT
Apr 25, 2024
CORRESP
CORRESP
Apr 25, 2024
ARS
ARS
Apr 25, 2024
DEF 14A
DEF 14A
Apr 25, 2024
DEFA14A
DEFA14A

Peers (Alternatives to Aprea Therapeutics Inc)

NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
55.6B
6.8B
13.11% 15.14%
-9.32
8.12
-64.45% -224.75%
22.5B
216.3K
-0.77% 465779.94%
-2.5K
104.0K
- -8.13%
20.2B
2.0B
8.19% -19.39%
-60.96
10.11
75.20% 68.82%
16.0B
2.5B
5.74% -10.79%
77.85
6.47
13.74% 186.89%
14.1B
3.8B
9.90% 2.05%
18.88
3.74
8.58% 129.81%
MID-CAP
5.4B
107.9M
0.17% 71.70%
-9.93
48.09
54.84% -28.31%
5.2B
524.1M
3.28% -53.81%
-12.38
9.86
394.93% 39.61%
3.4B
251.0M
-6.27% -10.41%
-11.62
13.72
73.58% -86.73%
3.3B
240.7M
15.67% -25.01%
-6.96
12.77
-1.03% -213.92%
2.5B
813.8M
1.62% -37.45%
-1.5K
3.06
56.43% 98.83%
2.1B
996.6M
11.65% 94.95%
-5.3
2.12
-26.66% 65.49%
SMALL-CAP
1.8B
411.3M
-7.16% 29.42%
27.77
4.4
60.38% -34.49%
564.4M
881.7K
22.84% 567.64%
-16.72
481.06
-77.61% 33.36%
244.6M
4.2M
-17.34% 57.33%
-1.96
58.8
-66.30% 48.24%
22.1M
2.1M
36.17% 271.01%
-0.95
7.61
-13.45% 69.54%

Aprea Therapeutics Inc News

Latest updates
Simply Wall St11 hours ago

Aprea Therapeutics Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)
(In Thousands)
Income Statement (Quarterly)
(In Thousands)
(*) denotes actual numbers (not divided by Thousands)
Description(%) Q/Q2024Q12023Q42023Q32023Q2
Revenue8.7%381350319250
Operating Expenses-4.3%3,5303,6893,8423,901
  S&GA Expenses17.4%1,9301,6431,7201,699
Net Income18.4%-2,810-3,443-3,204-3,259
Net Income Margin11.0%-21.80*-24.50*--
Free Cashflow-5.3%-3,943-3,746-2,258-3,233
Balance Sheet
(In Millions)
Balance Sheet
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2024Q12023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32018Q4
Assets46.6%33.0023.0026.0029.0032.0030.0034.0041.0050.0057.0062.0072.0080.0093.0010311512513457.0066.00
  Current Assets46.8%33.0023.0026.0029.0032.0030.0033.0040.0050.0057.0062.0071.0080.0092.0010211412513357.0066.00
    Cash Equivalents49.8%32.0022.0025.0028.0031.0029.0033.0039.0048.0053.0061.0070.0078.0089.0010111312313052.0066.00
  Net PPE2.1%0.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.00
Liabilities----4.004.003.004.008.007.007.009.0011.0011.0015.0014.0015.0012.009.0010.005.00
  Current Liabilities-32.4%3.004.004.004.004.003.004.008.007.007.009.0011.0011.0015.0014.0015.0012.009.0010.005.00
Shareholder's Equity70.6%29.0017.0020.0023.0026.0026.0027.00-44.0050.0053.0061.0069.0077.0089.00100113124--
  Retained Earnings-0.9%-310-308-304-301-298-293-291-287-189-181-173-163-153-144-128-116-99.93-90.53-77.46-62.47
  Additional Paid-In Capital4.4%35033633633533533032826224324123723523323123022922722620.0020.00
Shares Outstanding45.3%5.004.004.004.003.003.001.001.001.001.001.001.001.00-------
Float----10.00---14.00---70.00---264----
Cashflow (Last 12 Months)
(In Thousands)
Cashflow (Quarterly)
(In Thousands)
(*) denotes actual numbers (not divided by Thousands)
Description(%) Q/Q2024Q12023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q1
Cashflow From Operations-5.2%-3,935-3,739-2,241-3,216-2,979-4,020-6,592-8,902-5,495-10,178-8,233-7,751-11,522-13,199-11,423-9,638-7,541-14,742-2,793-4,975-4,197
Cashflow From Investing-11.6%-7.98-7.15------------16.29725*2.00-12.16-14.47-10.25--
Cashflow From Financing-14,710---5,14099.00---1,660-----12130.0091,198-3,619-4355,433
Get Full Access to Grufity – and Unlimited Downloads
Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.
Try For Just $1.99

APRE Income Statement

2024-03-31
Condensed Consolidated Statements of Operations and Comprehensive Loss - USD ($)
3 Months Ended
Mar. 31, 2024
Mar. 31, 2023
Condensed Consolidated Statements of Operations and Comprehensive Loss  
Grant revenue$ 380,569 
Operating expenses:  
Research and development1,600,373$ 1,256,542
General and administrative1,929,8663,365,961
Total operating expenses3,530,2394,622,503
Loss from operations(3,149,670)(4,622,503)
Other income (expense):  
Interest income, net283,403256,410
Foreign currency gain (loss)56,176(13,797)
Total other income339,579242,613
Net loss(2,810,091)(4,379,890)
Other comprehensive (loss) gain:  
Foreign currency translation(15,083)61,956
Total comprehensive loss$ (2,825,174)$ (4,317,934)
Net loss per share attributable to common stockholders, basic (in dollars per share)$ (0.67)$ (1.34)
Net loss per share attributable to common stockholders, diluted (in dollars per share)$ (0.67)$ (1.34)
Weighted-average common shares outstanding, basic (in shares)4,198,3263,260,484
Weighted-average common shares outstanding, diluted (in shares)4,198,3263,260,484

APRE Balance Sheet

2024-03-31
Condensed Consolidated Balance Sheets - USD ($)
Mar. 31, 2024
Dec. 31, 2023
Current assets:  
Cash and cash equivalents$ 32,369,973$ 21,606,820
Prepaid expenses and other current assets698,864914,275
Total current assets33,068,83722,521,095
Property and equipment, net90,18388,362
Restricted cash40,98640,717
Total assets33,200,00622,650,174
Current liabilities:  
Accounts payable1,318,3851,670,369
Accrued expenses1,498,2862,186,262
Deferred grant revenue148,405528,974
Total current liabilities2,965,0764,385,605
Commitments and contingencies (Note 7)
Stockholders' equity:  
Common stock, $0.001 par value, 400,000,000 shares authorized, 5,430,215 and 3,736,673 shares issued and outstanding at March 31, 2024 and December 31, 2023, respectively5,4303,736
Additional paid-in capital350,438,045335,644,204
Accumulated other comprehensive loss(10,626,356)(10,611,273)
Accumulated deficit(310,893,252)(308,083,161)
Total stockholders' equity28,923,86716,953,506
Total liabilities and stockholders' equity33,200,00622,650,174
Series A Convertible Preferred Stock  
Convertible preferred stock:  
Series A convertible preferred stock, $0.001 par value, 40,000,000 shares authorized; 56,227 shares issued and outstanding at March 31, 2024 and December 31, 2023$ 1,311,063$ 1,311,063
APRE
Aprea Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing synthetic lethality-based cancer therapeutics that targets DNA damage response pathways. Its lead product candidate is the ATRN-119 that is in Phase I clinical trials for treating advanced solid tumors, ovarian, breast, and prostate cancers. The company is also developing ATRN-1051, ATRN-354, and APRE-DDRi for the treatment of advanced solid tumors. The company is headquartered in Doylestown, Pennsylvania.
 CEO
 WEBSITEaprea.com
 INDUSTRYBiotechnology
 EMPLOYEES9

Aprea Therapeutics Inc Frequently Asked Questions


What is the ticker symbol for Aprea Therapeutics Inc? What does APRE stand for in stocks?

APRE is the stock ticker symbol of Aprea Therapeutics Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Aprea Therapeutics Inc (APRE)?

As of Thu Jun 13 2024, market cap of Aprea Therapeutics Inc is 22.97 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of APRE stock?

You can check APRE's fair value in chart for subscribers.

What is the fair value of APRE stock?

You can check APRE's fair value in chart for subscribers. The fair value of Aprea Therapeutics Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Aprea Therapeutics Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for APRE so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Aprea Therapeutics Inc a good stock to buy?

The fair value guage provides a quick view whether APRE is over valued or under valued. Whether Aprea Therapeutics Inc is cheap or expensive depends on the assumptions which impact Aprea Therapeutics Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for APRE.

What is Aprea Therapeutics Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Thu Jun 13 2024, APRE's PE ratio (Price to Earnings) is -1.81 and Price to Sales (PS) ratio is 39.38. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. APRE PE ratio will change depending on the future growth rate expectations of investors.